NCT07431827

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2026-03-18Est. Completion: 2039-10-26

Enrollment target: 400 participants

Locations

Instituto Alexander Fleming ( Site 0310), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Sanatorio Parque ( Site 0311), Rosario, Santa Fe Province, Argentina
Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 0309), CABA, Argentina
Peking Union Medical College Hospital ( Site 2105), Beijing, Beijing Municipality, China
Chongqing University Three Gorges Hospital ( Site 2138), Chongqing, Chongqing Municipality, China
The First Affiliated Hospital Of Fujian Medical University ( Site 2123), Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center ( Site 2134), Guangzhou, Guangdong, China
Guangxi Medical University Cancer Hospital ( Site 2115), Nanning, Guangxi, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 2139), Wuhan, Hubei, China
Sichuan Cancer hospital ( Site 2101), Chengdu, Sichuan, China
The Third Peoples Hospital Of Chengdu ( Site 2141), Chengdu, Sichuan, China
Ningbo No. 2 Hospital ( Site 2124), Ningbo, Zhejiang, China
Centre de Cancérologie du Grand Montpellier ( Site 1016), Montpellier, Languedoc-Roussillon, France

Other microbiome trials you might be interested in

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine TumorsPhase 2Recruiting

Advanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine TumorLocally Advanced Lung Neuroendocrine NeoplasmLung Neuroendocrine NeoplasmLung Neuroendocrine Tumor G1Lung Neuroendocrine Tumor G2Metastatic Lung Neuroendocrine NeoplasmMetastatic Lung Neuroendocrine TumorNon-Functioning Lung Neuroendocrine TumorRecurrent Lung Neuroendocrine NeoplasmUnresectable Lung Neuroendocrine NeoplasmUnresectable Lung Neuroendocrine Tumor

This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treat…

Birmingham, United StatesEst. completion Jul 1, 2027

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.